In vitro and in vivo antifungal activities of FX0685, a novel triazole antifungal agent with potent activity against fluconazole-resistant Candida albicans

Medical Mycology

Volumn 43, Issue 3, 2005, Pages 227-233

  Takahata, Sho ^a   Okutomi, Takafumi ^a   Ohtsuka, Keiko ^a   Hoshiko, Shigeru ^a   Uchida, Katsuhisa ^b   Yamaguchi, Hideyo ^b  

^a MEIJI SEIKA KAISHA LTD   (Japan)

^b TEIKYO UNIVERSITY   (Japan)

Author keywords

Candida albicans; CYP51; Triazole antifungal agent

Indexed keywords

6 (4 CYANOPHENYL) N [2 (2,4 DIFLUOROPHENYL) 2 HYDROXYMETHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL]N METHYL IMIDAZO[2,1 B]THIAZOLE 2 CARBOXAMIDE; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; FLUCONAZOLE; FX 0685; ITRACONAZOLE; PYRROLE DERIVATIVE; STEROL 14ALPHA DEMETHYLASE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; CROSS RESISTANCE; CRYPTOCOCCUS NEOFORMANS; DISEASE MODEL; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; FUNGAL STRAIN; GROWTH INHIBITION; IN VITRO STUDY; IN VIVO STUDY; LUNG ASPERGILLOSIS; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; OPPORTUNISTIC INFECTION; PHENOTYPE; SPECIES DIFFERENCE; STRAIN DIFFERENCE; TREATMENT OUTCOME;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; INJECTIONS, INTRAVENOUS; MALE; MICE; MICE, INBRED CBA; MICE, INBRED DBA; MICROBIAL SENSITIVITY TESTS; SPECIES SPECIFICITY; TRIAZOLES;

ASPERGILLUS FUMIGATUS; CANDIDA; CANDIDA ALBICANS; FILOBASIDIELLA NEOFORMANS; MURINAE;

EID: 20944438880     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/13693780410001731600     Document Type: Article

References (32)

1. Stein DK, Sugar AM. Fungal infections in the immunocompromised host. Diagn Microbiol Infect Dis 1989; 12(Suppl. 4): 221S-228.
2. Law D, Moore CB, Wardle HM, et al. High prevalence of antifungal resistance in Candida spp. from patients with AIDS. J Antimicrob Chemother 1994; 34: 659-668.
3. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekema DJ. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother 2002; 46: 1723-1727.
4. Sanglard D, Kuchler K, Ischer F, et al. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 1995; 39: 2378-2386.
5. White TC. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother 1997; 41: 1482-1487.
6. Sanglard D, Ischer F, Monod M, Bille J. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 1997; 143: 405-416.
7. Fling ME, Kopf J, Tamarkin A, et al. Analysis of a Candida albicans gene that encodes a novel mechanism for resistance to benomyl and methotrexate. Mol Gen Genet 1991; 227: 318-329.
8. Asai K, Tsuchimori N, Okonogi K, et al. Formation of azole-resistant Candida albicans by mutation of sterol 14-demethylase P450. Antimicrob Agents Chemother 1999; 43: 1163-1169.
9. Favre B, Didmon M, Ryder NS. Multiple amino acid substitutions in lanosterol 14α-demethylase contribute to azole resistance in Candida albicans. Microbiology 1999; 145: 2715-2725.
10. Lamb DC, Kelly DE, White TC, Kelly SL. The R467K amino acid substitution in Candida albicans sterol 14α-demethylase causes drug resistance through reduced affinity. Antimicrob Agents Chemother 2000; 44: 63-67.
11. Sanglard D, Ischer F, Koymans L, Bille J. Amino acid substitutions in the cytochrome P-450 lanosterol 14α-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother 1998; 42: 241-253.
12. Perea S, Lopez-Ribot JL, Kirkpatrick WR, et al. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance 6isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2001; 45: 2676-2684.
13. White TC, Holleman S, Dy F, Mirels LF, Stevens DA. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother 2002; 46: 1704-1713.
14. Maebashi K, Niimi M, Kudoh M, et al. Mechanisms of fluconazole resistance in Candida albicans isolates from Japanese AIDS patients. J Antimicrob Chemother 2001; 47: 527-536.
15. Denning DW, Venkateswarlu K, Oakley KL, et al. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 1997; 41: 1364-1368.
16. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved Standard; document no. M27-A. Wayne, PA: NCCLS, 1997.
17. Yamaguchi H, Uchida K, Nagino K, Matsunaga T. Usefulness of a colorimetric method for testing antifungal drug susceptibilities of Aspergillus species to voriconazole. J Infect Chemother 2002; 8: 374-377.
18. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Proposed Standard; document no. M38-P. Wayne, PA: NCCLS, 1998.
19. Vanden Bossche H, Marichal P, Odds FC, Le Jeune L, Coene MC. Characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother 1992; 36: 2602-2610.
20. Balzi E, Goffeau A. Genetics and biochemistry of yeast multidrug resistance. Biochim Biophys Acta 1994; 1187: 152-162.
21. Franz R, Kelly SL, Lamb DC, et al. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob Agents Chemother 1998; 42: 3065-3072.
22. Franz R, Ruhnke M, Morschhäuser J. Molecular aspects of fluconazole resistance development in Candida albicans. Mycoses 1999; 42: 453-458.
23. Lopez-Ribot JL, McAtee RK, Lee LN, et al. Distinct patterns of gene expression associated with development of fluconazole resistance in serial Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 1998; 42: 2932-2937.
24. Vanden Bossche H, Marichal P, Odds FC. Molecular mechanisms of drug resistance in fungi. Trends Microbiol 1994; 2: 393-400.
25. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998; 11: 382-402.
26. Kelly SL, Lamb DC, Loeffler J, Einsele H, Kelly DE. The G464S amino acid substitution in Candida albicans sterol 14ademethylase causes fluconazole resistance in the clinic through reduced affinity. Biochem Biophys Res Commun 1999; 262: 174-179.
27. Lamb DC, Kelly DE, Schunck WH, et al. The mutation T315A in Candida albicans sterol 14α-demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity. J Biol Chem 1997; 272: 5682-5688.
28. Katiyar SK, Edlind TD. Identification and expression of multidrug resistance-related ABC transporter genes in Candida krusei. Med Mycol 2001; 39: 109-116.
29. Sanglard D, Ischer F, Calabrese D, Majcherczyk PA, Bille J. The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents. Antimicrob Agents Chemother 1999; 43: 2753-2765.
30. Marichal P, Koymans L, Willemsens S, et al. Contribution of mutations in the cytochrome P450 14α-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology 1999; 145: 2701-2713.
31. Kelly SL, Lamb DC, Kelly DE. Y132H substitution in Candida albicans sterol 14α-demethylase confers fluconazole resistance by preventing binding to haem. FEMS Microbiol Lett 1999; 180: 171-175.
32. Kakeya H, Miyazaki Y, Miyazaki H, et al. Genetic analysis of azole resistance in the Darlington strain of Candida albicans. Antimicrob Agents Chemother 2000; 44: 2985-2990.